Ep. 171 - 2Q Markets Preview, Abortion Drug Rulings, Gilead Oncology
BioCentury This Week
00:00
The Importance of Positive Clinical Data in Biotech IPO Prospects
60% of NASDAQ listed biotechs are now under 200 million which is a number that sticks in my head. When you start getting down that low it makes it hard for the big funds to get in even if they wanted to and right obviously right now they don't want to but even if we were to reach a point where they did it's hard to get them in. We need to continue the positive clinical data trying to mean everyone says day-to-day-to-Day is important which it is I think we need to see a run of positive clinical data.
Transcript
Play full episode
